The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis

International Journal of Dermatology

Volumn 48, Issue 4, 2009, Pages 348-355

  Reitamo, Sakari ^a,b,c   Mandelin, Johanna ^a,b,c   Rubins, Andris ^a,b,c   Remitz, Anita ^a,b,c   Mäkelä, Mika ^a,b,c   Cirule, Kristine ^a,b,c   Rubins, Silvestrs ^a,b,c   Zigure, Sanita ^a,b,c   Ho, Vincent ^a,b,c   Dickinson, James ^a,b,c   Undre, Nasrullah ^a,b,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Riga Latvia and Clinical Trials   (Canada)

^c Astellas Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; TACROLIMUS;

APPLICATION SITE BURNING; APPLICATION SITE INFECTION; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EVENING DOSAGE; FEMALE; FURUNCULOSIS; HUMAN; IMPETIGO; INFANT; INFECTION; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; PRESCHOOL CHILD; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SKIN BURNING SENSATION; SKIN IRRITATION; THROMBOCYTHEMIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRAL UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, TOPICAL; DERMATITIS, ATOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 63549134458     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.03853.x     Document Type: Article

References (23)

1. Kristal L, Klein PA. Atopic dermatitis in infants and children. An update. Pediatr Clin North Am 2000; 47: 877-895.
2. Bos JD. Atopiform dermatitis. Br J Dermatol 2002; 147: 426-429.
3. Bos JD, Kapsenberg ML, Smitt JH. Pathogenesis of atopic eczema. Lancet 1994; 343: 1338-1341.
4. Kapp A. The role of eosinophils in the pathogenesis of atopic dermatitis - eosinophil granule proteins as markers of disease activity. Allergy 1993; 48: 1-5.
5. Lubach D, Bensmann A, Bornemann U. Steroid-induced dermal atrophy. Investigations on discontinuous application. Dermatologica 1989; 179: 67-72.
6. Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003; 148: 128-133.
7. Matsuda K, Katsunuma T, Iikura Y, et al. Adrenocortical function in patients with severe atopic dermatitis. Ann Allergy Asthma Immunol 2000; 85: 35-39.
8. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-936.
9. Cheer SM, Plosker GL. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001; 2: 389-406.
10. Goto T, Kino T, Hatanaka H, et al. FK 506: Historical perspectives. Transplant Proc 1991; 23: 2713-2717.
11. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: A phase I study in adults and children. J Am Acad Dermatol 1998; 38: 69-76.
12. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637-644.
13. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58-S64.
14. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51: 515-525.
15. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S47-S57.
16. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: Results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150: 554-562.
17. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-546.
18. Schachner LA, Lamerson C, Sheehan MP, et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: Results from a randomized, double-blind, vehicle-controlled study. Pediatrics 2005; 116: E334-e342.
19. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124: 695-699.
20. Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. J Drugs Dermatol 2007; 6: 185-193.
21. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) Supplement 1980; 92: 44-47.
22. Wallemacq PE, Furlan V, Moller A et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet 1998; 23: 367-370.
23. Rubins A, Gutmane R, Valdmane N, et al. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol 2005; 125: 68-71.